Master Class
Rakesh Jain, MD
Clinical Professor
Texas Tech - Permian Basin
Texas Tech University School of Medicine - Permian Basin, Midland, Texas
Maria Margaglione
Person with Lived Experience
Not applicable
The management of major depressive disorder (MDD) is an ongoing clinical challenge, especially considering the large proportion of patients who experience an inadequate response to initial antidepressant monotherapy. These patients experience a substantial burden with higher functional impairments and poorer clinical outcomes. In this MasterClass session, expert faculty will delve into the assessment of the prevalence and burden of poor response in individuals with MDD, exploring the limitations of traditional antidepressants that often contribute to this issue, offering insights into the factors underlying poor response. Participants will gain a profound understanding of the role of glutamatergic signaling in the pathophysiology of MDD and how this knowledge translates into potential therapeutic targets. Expert faculty will critically evaluate the mechanisms of action, pharmacokinetic profiles, and the latest clinical data associated with newer and emerging glutamatergic pharmacotherapies. By the end of the session, attendees will be equipped to implement therapeutic strategies that seamlessly integrate the latest clinical evidence into their informed treatment decisions.
Developed in partnership with Depression and Bipolar Support Alliance
Supported by an independent educational grant from Axsome Therapeutics, Inc.